RecruitingPhase 2NCT07132190

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

Studying PLA2G6-associated neurodegeneration

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ayal A. Aizer, MD
Principal Investigator
Ayal A Aizer, MD, MHS
Dana-Farber/Brigham and Women's Cancer Center
Intervention
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV(radiation)
Enrollment
60 target
Eligibility
18 years · All sexes
Timeline
2025 – 2029

Study locations (1)

Collaborators

Varian, a Siemens Healthineers Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07132190 on ClinicalTrials.gov

Other trials for PLA2G6-associated neurodegeneration

Additional recruiting or active studies for the same condition.

See all trials for PLA2G6-associated neurodegeneration →

← Back to all trials